Watch the videos, download the slides and take the e-learning

Loretta Nastoupil, MD, completed her undergraduate degree at Texas Tech Health Sciences Center, graduating summa cum laude in 2003. She obtained her medical degree from the University of Texas Southwestern Medical School at Dallas in 2007. Dr Nastoupil completed her internship and internal medicine residency at Washington University, Barnes-Jewish Hospital in St. Louis, Missouri. Following residency, she completed a hematology-medical oncology fellowship at Emory University, serving as chief fellow her last year. Dr Nastoupil joined the faculty at MD Anderson Cancer Center in 2013 as an assistant professor in the Department of Lymphoma/Myeloma. Dr Nastoupil is a clinical researcher with a focus on lymphoma epidemiology and outcomes. The goal of her research is to identify risk factors associated with lymphoma and eliminate disparities in outcomes to improve survival for all patients with lymphoma. She is actively involved in early phase drug development as well as immune therapy studies in indolent lymphoma. She is also actively exploring predictive biomarkers with modern therapy in lymphoma.

Assoc. Prof. Loretta Nastoupil has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, BMS, Genentech, Epizyme,Gilead/Kite, Novartis, TG Theraputics and Pfizer. 

Programme summary
Watch the video now
Other episodes of this series
Chemotherapy-free treatment approaches in lymphoma #1

Chemotherapy-free treatment approaches in lymphoma #1

Prof. Simon Rule provides an overview from the live meeting on Chemotherapy-free treatment approach in lymphoma. E-learning also available
Chemotherapy-free treatment approaches in lymphoma #2

Chemotherapy-free treatment approaches in lymphoma #2

Dr. Loretta Nastoupil shares an American Perspective on Chemotherapy-free treatment approach in lymphoma. E-learning also available Current Module
Chemotherapy-free treatment approaches in lymphoma #3

Chemotherapy-free treatment approaches in lymphoma #3

Prof. Stefano Luminari provides a European perspective on Chemotherapy-free treatment approach in lymphoma. E-learning also available
Share this programme
Supporter Acknowledgement
Accreditation
EACCME-accredited
This course has been accredited by EACCME® for ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LYMPHOMA & MYELOMA CONNECT

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.

Meet the experts Independent IME approved

Other programmes of interest

Hemato-oncology 
Update from ASCO 2022 – Myeloma

Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)

Experts
Asst. Prof. Hans Lee
  • clock 2 MIN
  • calendar May 2022

podcast Podcast

Episode

3

of 3

episode
Hemato-oncology 
Podcast: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics (Episode 3 of 3)

The third episode in the series, Dr. María Victoria Mateos and Dr. Alexander Lesokhin discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile

Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Mar 2022

Hemato-oncology 
Lymphoma Update from ASH 2021

Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL

Experts
Dr Matthew J. Matasar
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2021

publication Publication
Hemato-oncology 
DLBCL Review Paper Published in The Oncologist

Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.

Experts
Dr Matthew J. Matasar, Dr Massimo Magagnoli, Prof. Alexey V Danilov
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Nov 2021

conference-update Conference update
Hemato-oncology 
Update from the 2021 Autumn Congresses in Multiple Myeloma

Dr Claudio Cerchione summarises highlights from SOHO, SOHO Italy and IMW 2021

Experts
Dr Claudio Cerchione
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Nov 2021

podcast Podcast

Episode

2

of 3

episode
Hemato-oncology 
Podcast: Choosing the Best Treatment Regimen in RRMM (Episode 2 of 3)

In this second episode, Dr. Joshua Richter and Dr. Karthik Ramasamy discuss their views on choosing the best treatment regimen in relapsed/refractory multiple myeloma (RRMM)

Experts
Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Oct 2021